跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
tri-specific antibodies
首页
药物
tri-specific antibodies
tri-specific antibodies
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
NOVEL ANTIBODIES THAT BIND TO CD3 AND LILRB4, AND USES THEREOF
WO 2025119253 A1
申请人: ANTENGENE HANGZHOU BIOLOGICS CO LTD
优先权: 2023
CN
WO
2 件公开
Tri-specific binding molecules and methods of use thereof
CN 113416252 A
申请人: MACROGENICS INC
优先权: 2014
CN
2 件公开
HIV-1 Env-binding antibodies, fusion proteins, and methods of use
CN 104955847 A
申请人: UNIV MARYLAND
优先权: 2013
CN
Tri-specific antibodies for HIV therapy
US 10654943 B2
申请人: UNIV ROCKEFELLER
优先权: 2016
US
Tri-specific antibodies
US 11649286 B2
申请人: SYSTIMMUNE INC
优先权: 2018
US
DUAL ACTING CD1D IMMUNOGLOBULIN
CN 113272325 A
申请人: STICHTING VU VUMC
优先权: 2018
CN
Tri-SPECIFIC T-CELL ADAPTER
CN 116096751 A
申请人: GENSUN BIOPHARMA INC
优先权: 2020
CN
Tri-specific antibodies and uses
CN 115215938 A
申请人: SHANGDONG NEW TIME PHARM PROD
优先权: 2021
CN
BI-SPECIFIC ANTIBODIES COMPRISING ANTI-B7H3 BINDING MOLECULES
US 2024218069 A1
申请人: LYVGEN BIOPHARMA HOLDINGS LTD
优先权: 2021
US
Tri-specific antibodies, methods of making and uses thereof
CN 115536749 A
申请人: SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD
优先权: 2021
CN
第 1 / 3 页
上一页
下一页
药物
反馈